Open Label Extension (OLE) of the TDF2 Study, Botswana
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study is an open label and is an extension to the TDF2 study in which the investigators
offered daily oral tenofovir/emtricitabine (TDF/FTC) for a maximum of 12 months to HIV
uninfected former participants of the TDF2 study.